International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume 6 Issue 4, May-June 2022 Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470

Overview of Transdermal Drug Delivery System

Sayali Dhepe*, Manisha Sukre, Vikram Veer

P.D.E.A.'s Shankarrao Ursal College of Pharmaceutical Sciences and Research Centre, Kharadi, Pune, Maharashtra, India

ABSTRACT

Transdermal drug delivery systems are topically administered medicaments. Transdermal drug transport structures (TDDS) are the dosage shape of adhesive patch this is positioned on the skin to deliver specific dose of medication through the skin and in to the blood stream. The main objective of transdermal drug delivery system is to deliver drug into systemic circulation through skin at predetermined rate with minimal inter and intrapatients variation. This article gives a brief overview over principles behind transdermal drug delivery, as well as the advantages and disadvantages of transdermal therapeutic system and the recent innovations in the field of transdermal drug delivery and also describe the methods of preparation of different types of transdermal patches, evaluation parameters and some available marketed products.

KEYWORDS: *Epidermis, Transdermal drug delivery system, skin*

**Corresponding Author: Sayali Dhepe*

How to cite this paper: Sayali Dhepe | Manisha Sukre | Vikram Veer "Overview of Transdermal Drug Delivery System" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-4, June 2022, pp.670-682, URL: www.ijtsrd.com/papers/ijtsrd50107.pdf

IJTSRD50107

INTRODUCTION

The first transdermal system, transdermal Scop (Baxter), was approved by Food and Drug administration in 1979 for the prevention of nausea and vomiting associated with travel, particularly at sea. Transdermal drug transport gadget includes all topically administered drug formulations intended to deliver the active ingredients into the circulation. Transdermal delivery provides a leading edge over injectable and oral routes by increasing patients' compliance and avoiding first pass metabolism. The transdermal drug delivery system (TDDS), Commonly Known as "patches" is a dosage form that is designed to distribute a therapeutically effective amount of drug over the skin of a patient. Transdermal delivery provides a leading edge over injectable and oral routes by increasing Patients compliance avoiding first pass metabolism. The transdermal drug delivery system (TDDS), know as patches, is a dosage from that is designed to distribute a therapeutically effective amount of drug over the skin of a patient. Transdermal drug shipping is the non-invasive transport of medicines from the floor of medications from the surface of skin. Transdermal drug delivery system (TDDS) are dosage forms designed to deliver a therapeutically effective dose of drug across a patient's skin.

- **DEFINATION: -** Transdermal drug shipping systems are topically administered medicaments inside the shape of patch that deliver drugs for systemic effects at a predetermined and controlled rate.

- **ADVANTAGES OF TRANSDERMAL DRUG DELIVERY SYSTEM: -**

1. First pass metabolism of drug get avoided.
2. Transdermal medication delivers a steady infusion of the drug over prolonged period of time, therefore avoiding side effects and therapeutic failure frequently associated with intermittent dosing can also be avoided.
3. Reducing the typical dosing schedule to once daily.
4. Avoiding of gastrointestinal incompatibility.
5. Ability to deliver the drug more selectively to a specific site.
6. It can be used as an alternate to oral drug delivery system for those patients, who find difficulty in taking drugs through oral route.

7. Self-administration can be done.
8. Transdermal drug delivery enables the avoidance of gastrointestinal absorption with its associated pitfalls of enzymatic and pH associated deactivation.
9. Provide utilization of drug with short biological half-lives, narrow therapeutic window.
10. This method avoids direct effect on stomach and intestine.
11. Continuity of drug administration permitting the use of the drug with short biological half-life.
12. Number of doses get reduces which improves patient compliance.
13. Predictable and extended duration of activity.
14. Enhance therapeutic efficacy.
15. Offers long duration of action.
16. System changes of allergic reaction at the site of application like itching, rashes, local edema etc.

- **DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY SYSTEM:**

1. Many drugs with a hydrophilic structure permeate the skin too slowly to be therapeutic benefit.
2. Drug with hydrophilic character is less suitable with lipophilic character because of low permeability.
3. Drug having affinity for both lipophilic and hydrophilic phases.
4. Long time adhere is difficult.
5. Only relatively potent drugs are suitable candidates for TDDS because natural limit of drug entry imposed by skin impermeability.

- **Anatomy of the Skin: -**

Transdermal drug act through the largest organ of the body i.e., Skin.

Skin structure: - The pores and skin's number one role is to defend the body from germs, ultraviolet (UV) radiation, chemical compounds, allergies, and water loss by acting as a barrier between the body and the external environment. With a surface area of 1.7 m2, skin is the most accessible and largest organ of the body, accounting for 16 percent of an average person's total body mass.



Figure: Structure of Skin

The three main regions of the skin are

1. The dermis, which incorporates the stratum corneum, is the outermost layer of the skin.
2. The epidermis, the middle layer, and
3. The hypodermis is innermost layer of the skin

Epidermis: - The epidermis

- The viable epidermis
- A non-viable epidermis (Stratum corneum)
- The stratum corneum is the epidermis' maximum superficial layer. The dermis is stratified squamous epithelium. The main cells of the dermis are the keratinocytes, which synthesis the protein keratin. Protein bridges known as desmosomes connect the keratinocytes, that are in a regular kingdom of transition from the deeper layers to the superficial.
- The multi-layered epidermis varies in thickness, depending on cell size and number of cell layers of epidermis, ranging from 0.8 mm on palms and soles down to 0.06 mm on the eyelids.

- The epidermis varies in with water-retaining keratin proteins. The mobile form and orientation of the keratin proteins upload power to the stratum corneum.
- The movement of epidermal cells to this generally takes approximately 28 days and is known as the epidermal transit time.



- **Dermis: -**

- Dermis is the layer of skin simpy underneath the epidermis that is 3 to 5 nm thick layer and is composed of a matrix of connective tissues, which contains blood vessels, lymph vessels and nerves. The cutaneous blood supply has important feature in regulation of body temperature. It also offers vitamins and oxygen to the pores and skin while removing pollution and waste merchandise.
- The dermis is round 2–3 mm thick and is made of collagenous (70%) and elastin fibers, which offer the skin energy and versatility.
- The dermis includes blood arteries that supply nutrients to both the epidermis and the dermis.

Two layers comprise the dermis: -

- A thin papillary layer
- A thicker reticular layer.



- **Hypodermis: -**

➢ The hypodermis, additionally known as the subcutaneous layer, is the pores and skin's lowest layer and is made up of a network of fat cells. It's miles the layer that connects the skin to the frame's underlying tissues, inclusive of muscle groups and bone. It carries most important blood vessels and nerves to pores and skin and may include sensory pressure organs.

➢ The hypodermis layer consists of free connective tissues and its, thickness varies according to the surface of body. As a result, the hypodermis' main roles are physical shock protection, heat insulation, and support and conductance of the skin's vascular and neurological signals.

➢ For transdermal drug delivery, drug has to penetrate via most of these 3 layers and attain into systemic circulation while in case of topical drug delivery only penetration through stratum corneum is critical after which retention of drug in skin layers is favored.



- **Components of TDDS: -**

Transdermal drug delivery system basic components: -

1. The drug.
2. Polymer matrix.
3. Permeation enhancers.
4. Adhesive.
5. Backing layer.
6. Release linear.

1. Drug:

Drug that may be administered via transdermal drug shipping machine are decided on after considering the different properties of the drug that includes physiological, chemical, and biological along with the Pharmacodynamics and pharmacokinetic property. Moreover, the 1/2-lifestyles, destructive effect of transdermal drug transport device with other course such as oral or I.V. dose is also taken into consideration at some point of the choice of medicine for transdermal drug delivery system.

A. Physicochemical Properties: Under physicochemical properties following properties are expected from an ideal drug for transdermal drug delivery system.

➢ The drug that has to be delivered through TDDS should have a molecular weight less than 1000 Daltons.
➢ The drug should be having similar kind of affinity towards both the phases whether it is lipophilic or hydrophilic.
➢ Drug need to be having a pH that does not reason undesirable harm to the skin so the pH in the range of 4.2 TO 5.6
➢ Melting point of the drug ought to be low.

B. Biological Properties:

➢ Efficiency of drug must be such that in a dose of few mg/day it could exert the therapeutic effect.
➢ Drug need to have a quick half-life.

- As the drug is to be administered thru the skin then it need to be non-allergic to the recipient.
- The maximum suitable drug for which TDDS can be used is the drugs with high first bypass metabolism.

Types of Polymers used in TDDS

Sr. No	Name of Polymers	Type of polymer	Function
1	Gelatine, Na-alginate, natural Rubber, Gum tragacanth	Natural	Base and Adhesive
2	Carmellose, Methyl and ethyl cellulose Hydroxyl propyl cellulose	Semi synthetic	Base, adhesive
3	Styrene-butadiene rubber Silicone rubber	Synthetic elastomers	Base with adhesive
4	Polyvinyl alcohol polyethylene Polyhydroxyethyl methacrylate (PHMA)	Synthetic polymer	Base, adhesive Linear, backing

Ideal polymer should be having the following properties:

- It ought to now not react with the drug that it contains.
- It ought to no longer be having any effect of its personal.
- It have to be strong enough that it does not get decomposed for the duration of storage or till the existence span of the drug embedded in it.
- It should not be reactive to skin.
- It need to permit the diffusion of drug at desired price.

2. **Penetration enhancer: -** Permeation enhancer are described as substance which are successful of promoting penetration of drugs into skin and transdermal therapeutic systems offers a more reliable mean of administering drug through the skin.

Properties of penetration enhancers: -

1. They ought to be pharmacologically inactive within the body. In other words, it shouldn't bind to receptor sites.
2. It have to be reliable, irritant-unfastened, and hypersensitivity-unfastened.
3. The onset of impact ought to be short, and the period of pastime need to be predictable and appropriate for the drug being taken.
4. When the enhancer is eliminated, the attractive layer have to fast and absolutely regain its barrier properties.
5. While the barrier traits of the skin are eliminated, they should restore quickly and completely.
6. All medications and adjuvants to be formulated in topical treatments and devices should be chemically and physically compatible with the accelerant.
7. It should be a suitable solvent for drugs if it is liquid and will be utilised in large volume fractions.
8. It should spread evenly on the skin and have a pleasing "feel" thereto.
9. It should be easy to make dermatological preparations, transdermal devices, and skin adhesives from it.



Advantages and Disadvantages of penetration enhancers: -

Advantages

1. Using penetration enhancers, increase the drug's penetration fee to a level that is sufficient for therapeutic efficacy.
2. It's far beneficial for facilitating the absorption of non absorbable medicine through the pores and skin .
3. It may sell transdermal absorption of topical coaching.
4. Terpenes in propylene glycol solution ,consisting of limonene, are precise penetration enhancers for cytotoxic capsules.
5. It also serves as a charge limiter.

Disadvantages :-

1. The effective attention of a drug differs from one drug to the next.
2. Using diverse penetration enhancers in various concentrations is entirely prohibited.
3. The physicochemical houses of enhancers have a power at the body's aspect consequences.

Types of penetration enhancers: -

1. Chemical enhancers: -

Mechanism of action: -

They act with the aid of three mechanisms

1. With the aid of disrupting the stratum corneum's lipid shape, which is pretty organised.
2. By interplay with intercellular protein.
3. Through progressed drug or solvent partitioning into the stratum corneum.



Examples:

1. Sulphoxides and similar chemicals-dimethyl sulphoxide (DMSO), dimethyl formamide (DMF), dimethyl acetamide (DMAC)
2. Azones
3. Pyrrolidones

2. Drug vehicle based: -

Mechanism

Interaction of enhancers with the stratum corneum and the development of a SAR for enhancers with the best properties and the least toxicity.

Example

Ion pairs and complicated coacervates chemical capability adjustment.

3. Natural penetration enhancers

Mechanism Mechanism for Terpenes it may boom one or more of following results

1. Partition coefficient
2. Diffusion coefficient
3. Lipid Extraction
4. Drug Solubility
5. Macroscopic Barrier Perturbation
6. Molecular Orientation of Terpenes Molecule with Lipid Bilayer.

Example
1. Terpens-Menthol, Linalool, Limonene, Carvacrol.
2. Crucial oil-Basil oil, Neem oil, Eucalyptus, Chenopodium, Ylang- Ylang.

4. Adhesives: -

All transdermal devices are attached to the skin with a pressure sensitive adhesive that can be placed on the device's face or in the rear and extends peripherally. Both adhesive systems must meet the following requirements:
1. It should aggressively attach to the skin and be easily removed.
2. Shouldn't go away a sticky residue at the pores and skin that can't be washed off.
3. Skin need to not be irritated or sensitised, as an example, Silicones, and polyisobutylene.

5. Backing membrane: -

Backing membranes are flexible and offer a good binding to the drug reservoir, as well as preventing the drug from escaping through the top of the dosage form and allowing printing.



For example, Metallic plastic, is an impermeable substance that protects the product while it is being used on the skin. as an example, cellulose derivatives and polypropylene silicon.

Linear: During storage, keep the patch safe. Before using, the linear is removed.

- **Types of TDDS:**

1. Single-layer Drug-in-Adhesive
2. Multi-layer Drug-in-Adhesive
3. Reservoir
4. Micro reservoir system

- **Single-layer Drug-in- Adhesive**: On this kind the adhesive layer contains the drug. The adhesive layer not handiest serves to adhere the various layers collectively and additionally liable for the freeing the drug to the pores and pores and skin. The adhesive layer is surrounded by means of a transient liner and a backing.



Fig Single layer drug-in-adhesive

- **Multi-layer Drug-in-adhesive:** This type is likewise similar to the unmarried layer however it consists of a on the spot drug launch layer and other layer could be a managed launch along side the adhesive layer. The adhesive layer is responsible for the releasing of the drug. This patch additionally has a brief liner-layer and a everlasting backing.



Fig. Multi-layer drug-in-adhesive.

- **Reservoir system:** In this gadget the drug reservoir is embedded between an impervious backing layer and a fee controlling membrane. The drug releases simplest via the rate controlling membrane, which may be micro porous or non-porous. within the drug reservoir compartment, the drug can be in the shape of a solution, suspension, gel or dispersed in a solid polymer matrix. Hypoallergenic adhesive polymer may be carried out as outer floor polymeric membrane that is well matched with drug.



Fig. Reservoir system

- **Micro reservoir system:** In this type the drug delivery machine is a mixture of reservoir and matrix-dispersion gadget. The drug reservoir is formed by using first suspending the drug in an aqueous solution of water-soluble polymer and then dispersing the solution homogeneously in a lipophilic polymer to form thousands of unreachable, microscopic spheres of drug reservoirs. This thermodynamically volatile dispersion is stabilized quick by means of right now pass-linking the polymer in situ through the usage of pass linking marketers.



Fig. Matrix system

- **Evaluation of TDDS:**

The transdermal patches can be characterized in terms of following parameters:

- Physicochemical evaluation
- In vitro evaluation
- In vivo evaluation

Physicochemical evaluation:

TDDS can be physio-chemically evaluated in terms of these parameters:

1. **Thickness**: The thickness of transdermal film is determined by travelling microscope, dial gauge, screw gauge or micro meter at different points of the film.

2. **Uniformity of weight**: Weight variation is studied by individually weighing 10 randomly selected patches and calculating the average weight. The individual weight have to not deviate notably from the common weight.

3. **Drug content determination**: An as it should be weighed portion of movie (approximately 100mg) is dissolved in 100 mL of suitable solvent wherein drug is soluble after which is soluble and then the solution is shaken continuously for 24 hrs in shaker incubator. Then the whole solution is sonicated. After sonication and subsequent filtration, drug in solution is anticipated spectrophotometrically by means of suitable dilution. Concentration of drug is calculated by using standard graph.

4. **Folding endurance: -** A strip of a specified area must be cut uniformly and folded repeatedly at the same place until it breaks. The value of the folding endurance was determined by the number of times the film could be folded in the same place without breaking.

5. **Percentage moisture content: -** The prepared films are to be weighed individually and to be kept in a desiccator containing fused calcium chloride at room temperature for 24 hours. After 24 hour the films are to be reweighed and decide the share moisture content material from the beneath stated formula:

   Percentage moisture content = [initial weight- final weight/ final weight] × 100.

6. **Tensile strength: -** To determine tensile strength, polymeric films are sandwiched separately by corked linear iron plates.
   The tensile power can be calculated the use of the subsequent equation.
   Tensile strength= F/a. b (1+L/l)
   In which, F is the pressure required to break; a is width of movie; b is thickness of film; L is period of movie; l is elongation of movie at destroy point.

7. **Flatness:** A transdermal patch should possess a smooth surface and should not constrict with time. This could be tested with flatness examine.
   % Constriction = (I1 – I2) X 100
   Where, I2 = Final length of each strip and
   I1 = Initial length of each strip

➢ **IN VITRO RELEASE STUDIES:**

Drug launch mechanisms and kinetics are traits of the dosage forms which play an important position in describing the drug dissolution profile from a managed launch dosage paperwork and hence their in vivo performance. A number of mathematical models have been developed to describe the drug dissolution kinetics from controlled release drug delivery system.

There are various methods available for willpower of drug release fee of TDDS.

- The Paddle over Disc: (USP apparatus 5/ PhEur 2.9.4.1) This method is identical to the USP paddle dissolution apparatus, except that the transdermal system is attached to a disc or cell resting at the bottom of the vessel which contains medium at 32 ±5°C

- The Cylinder changed USP Basket: (USP apparatus 6 / PhEur 2.nine.4.three) this technique is just like the USP basket type dissolution apparatus, except that the gadget is connected to the surface of a hollow cylinder immersed in medium at 32 ±5°C The amount of drug available for absorption to the systemic pool is greatly dependent on drug released from the polymeric transdermal movies. The drug reached at skin surface is then handed to the dermal microcirculation with the aid of penetration through cells of dermis, among the cells of dermis thru pores and skin appendages. practise of skin for permeation research: Hairless animal skin and human cadaver skin are used for permeation studies. Human cadaver pores and skin can be a logical preference as the pores and skin version because the very last product might be used in humans. but it isn't always easily available. So, hairless animal skin is usually preferred as it's miles effortlessly received from animals of particular age group or intercourse.

➢ **In vivo studies:**

Transdermal patches may be in vivo evaluated in phrases of in vivo evaluations are the true depiction of the drug performance. The variables which cannot be taken into account during in vitro studies can be completely explored during in vivo studies. In vivo assessment of TDDS may be performed the usage of animal fashions human volunteers.

Animal models: Great time and resources are required to perform human research, so animal research are desired at small scale. The most not unusual animal species used for comparing transdermal drug delivery device are mouse, hairless rat, hairless dog, hairless rhesus monkey, rabbit, guinea pig and many others. numerous experiments conducted leads to a conclusion that hairless animals are preferred over furry animals in both in vitro and in vivo experiments. Rhesus monkey is one of the most dependable models for in vivo assessment of transdermal drug transport in man.

Human model: The final level of the improvement of a transdermal device involves series of pharmacokinetic and pharmacodynamics information following software of the patch to human volunteers. Clinical trials had been carried out to assess the efficacy, risk worried, side outcomes, patients compliances and many others. Segment-I medical trials are carried out to determine specially protection in volunteers and segment II scientific trials decide quick time period safety and mainly effectiveness in patients. Segment III trials indicates the safety and effectiveness in big wide variety of affected person population and segment –IV trials at publish advertising surveillance are executed for marketed patches to discover destructive drug reactions. Although human studies require giants resources exceptional to assess the performance of the drug.

- **New Approaches in TDDS:**



1. **Iontophoresis**: It includes utility of contemporary (few mill-amperes) to the drug reservoir with equal charged electrode. there is possibility of increasing the stratum corneum permeability in the presence of an electric modern-day. Pilocarpin delivery may be taken for instance to set off sweat inside the diagnostic of cystic fibrosis and Iontophoretic delivery of idocaine is considered as speedy method for anaesthesia.



2. **Reverse Iontophoresis**: Symmetrical nature of iontophoresis (that transports ions throughout the the skin in both directions of the membrane) has led to its application as a non-invasive method of extracting endogenous substances known as REVERSE IONTOPHORESIS (RI). It's miles

considered as capacity device for therapeutic tracking. Additionally advised for non-invasive monitoring of Phenylketonuria by way of food and Drug administration in 2001.

3. **Photomechanical Waves:** Photomechanical waves significantly led to the stratum cornea highly permeable to drug substance through a possible permeabilization mechanism due to development of transient channels.
4. **Electroporation**: The electric pulses are taken into consideration to form small pores within the stratum corneum, through which transportation of drug occurs. For the sake of safe and painless administration, the electrical pulses introduced by closely spaced electrodes to reserve the electric field within the stratum corneum.

➢ **Patentability on TDDS: -**

Transdermal drug transport represents one of the most hastily advancing areas of novel drug shipping. even though the concept of transdermal drug transport has been acknowledged considering the fact that 1924, it took till 1979, as FDA accredited the transdermal delivery of scopolamine, that transdermal delivery structures [TDDS] received huge interest as novel tool for managed release. these drug shipping structures are designed for managed launch of drug via the skin into systemic move preserving constant efficacy and decreasing dose of the drug and its associated aspect effects. extra than two hundred patents were granted by using the United nation patent by myself, of which greater than 35 TDD products have now been accepted for sale within the US, and approximately sixteen lively elements had been accredited for use globally. information monitor a marketplace of $ 12.7 billion inside the yr 2005 that's predicted to increase with the aid of $ 21.5 billion within the 12 months 2010 and $ 31.five billion inside the 12 months 2015. nearly all main and minor pharmaceutical agencies are developing TDDS. There isn't always a single assessment article which describes patents on exceptional kinds of TDDS. as a consequence, this evaluation is designed for patents at the extraordinary type of TDDS which would be helpful for the researcher inside the field of TDDS.

➢ **Future prospective of TDDS: -**

The market for transdermal gadgets has been expected at U.S. $2 billion (Barry 2001) and this discern represents 10% of the general U.S. $28 billion drug shipping market. Such figures are surprising while we consider that the first transdermal patch changed into granted a licence by using the FDA in 1979, and simplest an extra nine capsules were accredited considering the fact that that time. This quick list of “deliverables” highlights the physicochemical regulations imposed on pores and skin shipping. Transdermal drug shipping has experienced a healthful annual growth rate of 25%, which outpaces oral drug delivery (2%) and the inhalation marketplace (20%) (Grosh 2000). This discern without a doubt DERMAL AND TRANSDERMAL delivery structures 185 will upward thrust inside the destiny as novel devices emerge and the listing of marketed transdermal tablets increases. The emergence of such gadgets will increase the use of the pores and skin as a route of management for the remedy of a variety of situations. however, subjective and objective analysis of these gadgets is required to make certain clinical, regulatory, and consumer desires are met. The devices in development are more steeply-priced and complicated as compared with traditional transdermal patch treatment plans. As such they will incorporate electric and mechanical components that would growth the ability protection risks to patients due to poor operator method or device malfunction. similarly, outcomes of the device at the skin need to be reversible, since any permanent harm to the stratum corneum effects within the lack of its barrier residences and as a result its function as a protecting organ. Regulatory our bodies additionally will require records to verify the safety of the device at the pores and skin for both quick- or long-term use. as a result, for any of these novel drug shipping technologies to be successful and compete with the ones already on the market, their safety, efficacy, portability, person-friendliness, cost-effectiveness, and potential market need to be addressed. The improvement of transdermal delivery systems involves balancing elevated transdermal delivery with affected person safety/comfort and value. due to the fact intact skin is not sufficiently permeable to the big majority of medicine, enhancement methods are wished. in spite of good sized studies for the duration of the past few many years, chemical enhancers have performed only limited achievement in growing transdermal shipping of small molecules and feature simplest a especially negative capacity to boom macromolecular delivery underneath situations likely to be clinically desirable. methods regarding ultrasound and electric powered fields, which include iontophoresis and electroporation, have more significantly elevated transdermal delivery for small tablets and macromolecules. The ability of those technologies to deliver drugs efficaciously is in part counterbalanced by using their reliance on electronically controlled gadgets that require an energy supply, which constrains programs and price. techniques that pierce micron-scale holes in pores and skin, including microneedles, thermal poration and jet injection, can

dramatically increase transdermal shipping of small tablets, macromolecules or even particles, but more paintings is wanted to set up safety/pores and skin harm and price effectiveness. every of those technologies is probably to in shape the wishes of different applications and, in a few instances, mixtures of enhancers might be the simplest strategy. Given the development being made on novel enhancement strategies, it appears that evidently transdermal drug transport has handiest scratched the surface of viable clinical impact. The defining feature of transdermal delivery that motivates the improvement of enhancement strategies is that the drug reservoir stays outside the frame, which presents a number of possibilities. as an example, a patient or healthcare company has clean access to a transdermal device that may be adjusted to modulate transport thru the right interface. by means of comparison, it's miles tough to regulate drug-launch kinetics after management by using other routes, inclusive of the gastrointestinal tract, the lungs or in the body. An outside transdermal tool also has fewer cost and substances boundaries as compared with some other approaches. Degradation and excretion of device substances are not applicable, and high priced electronics or different features may be designed into a re-usable transdermal gadget. For these reasons, transdermal transport arguably gives the greatest facility for managed launch of drugs. Overcoming the roadblock of low pores and skin permeability the use of the processes described in this assessment could be the vital improve that shall we transdermal delivery recognize its tremendous promise.

Conclusion: -

In recent times, the TDDS turning into a most broadly used routes of drug management directly into bloodstream without any pain and without rupturing skin membrane. This article gives valuable information about the overview of transdermal drug delivery system its advantages, disadvantages, Anatomy and physiology of skin, components of TDDS, types of TDDS, Evaluation of TDDS, new approaches in transdermal drug delivery system.

➢ **References: -**

[1] Audumbar D.M, Ritesh B, and Manojkumar P. An updated review on transdermal drug delivery systems. International Journal of Advances in Scientific Research 2015; 1(06): 244-254.

[2] Himanshi T, and Ruchika S. TRANSDERMAL DRUG DELIVERY SYSTEM: A REVIEW. International Journal of Advances in Scientific Research 2016; Vol. 7(6): 2274-2290.

[3] Sajid A, Maryam S, Nabeel S. The Structure of Skin and Transdermal Drug Delivery System-A Review. Research J. Pharm. and Tech.8 (2): February 2015 ,103-109.

[4] Siddhant S, Santosh W and Hemant K. A REVIEW: TRANSDERMAL DRUG DELIVERY SYSTEM. World Journal of Pharmaceutical Research, Volume 10, Issue 10, 381-402.

[5] Menon G.K. New Insights into Skin Structure: Scratching the Surface. Adv. Drug Delivery. Rev, 2002; 54: S3–S17. doi: 10.1016/S0169-409X(02)00121-7.

[6] Chein Y.W. Transdermal drug delivery and delivery system. In, Novel drug delivery system, Marcel Dekker, Inc., New york, 1992; 50: 301-381.

[7] Srivastava S, Maurya A, Gupta P. A review article on transdermal drug delivery system. World J Pharm Pharm Sci, 2016; 5: 1702-25.

[8] Tyagi S, Goyal K. Transdermal drug delivery system: Quality approaches and evaluation. Innov Int J Med Pharm Sci, 2017; 2: 15-21.

[9] Sharma N, Agarwal G, Rana A, Bhat ZA, Kumar D. A review: Transdermal drug delivery system: A tool for novel drug delivery system. Int J Drug Dev Res, 2011; 3: 70-84

[10] Prabhakar V, Shivendra A, Ritika S, Sharma S. Transdermal drug delivery system: review. Int Rese J Pharm, 2012; 3(5): 50-53.

[11] Willams A.C and barry B. W., "Penetration Enhancers," Adv. Drug Del. Rev, 2004; 56: 603-618.

[12] Shingade GM, Aamer Q, Sabale PM, Gramprohit ND, Gadhave MV, Jadhv SL, Gaikwad DD, Review on: recent trend on transdermal drug delivery system, Journal of Drug Delivery & Therapeutics. 2012; 2 (1), 66-75.

[13] Patel D, Sunita A, Parmar B, Bhura N, Transdermal Drug Delivery System: A Review, the Pharma Innovation. 2012; 1(4), 66-75.

[14] Sharma N, Agarwal G, Rana AC, Ali Bha Z, Kumar D, A Review: Transdermal Drug Delivery System: A Tool For Novel Drug Delivery System, International Singh et al, Journal of Drug Development & Research. 2011; 3(3), 70-84.

[15] Hanumanaik M, Patil Kumar, Patel SK, Singh I, Jadatkar K, Design, Evaluation and Recent Trends in Transdermal Drug Delivery System: A Review, International Journal of pharmaceutical sciences and research. 2012; 3(8),2393- 2406.

[16] Hock Tan S, William R, Pfister. Pressure-sensitive adhesives for transdermal drug delivery systems. PSTT. 1999; 2: 60-69.

[17] Gaikwad A, Transdermal drug delivery system: Formulation Aspect and Evaluation. Comprehensive Journal of Pharmaceutical Sciences. 2013; Vol. 1(1) ,pp. 1 – 10

[18] Benson H, Transdermal drug delivery: penetration enhancement techniques, Curr. Drug Deliv. 2005; 2, 23–33.

[19] Rajesh M and Kishor D. A Review on Transdermal Drug Delivery System. Research J. Science and Tech. 2011; 3(5): 227-231.

[20] Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems, Pharmaceutical Technology 2002, 62-78. Available from: www.pharmtech.com. Accessed on 15 Jan,2008.

[21] Bang AK. Electrically Assisted Transdermal and Topical Drug Delivery. Bristol, PA: Taylor and Francis, Inc.;1998.

[22] Finnin BC, Morgan TM. Transdermal penetration enhancers: applications, limitations, and potential. J Pharm Sci. 1999:88(10):955-958.

[23] Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin's barrier function. PSTT. 2000:3(9):318- 326

[24] Baker RW, Heller J. Material selection for transdermal delivery systems; In: Hadgraft J, Guys RH, editors. Transdermal Drug Delivery: Development Issues and Research Initiatives. New York, Marcel Dekker Inc. 1989; 293-311.

[25] Kaza R, Pitchaimani R. Formulation of transdermal drug delivery system: Matrix and selection of polymer- their evaluation, Current Drug Discovery Technologies 2006, 3, 279-285.

[26] Parikh DK, Tapash KG. Feasibility of transdermal delivery of fluoxetine, AAPS PharmSciTech. 2005, 6, E144-149.

[27] Babu RJ, Pundit JK. Effect of permeation enhancers on the transdermal delivery of bupranolol through rat skin, Drug Delivery 2005, 12, 165-169.

[28] A Text book of Pharmaceutical Dosage forms and Drug Delivery system by Howard C. Ansel, Nicholas G.Popovich; page no. 357-359.

[29] Bhowmik D, Chiranjib,. Recent advances in transdermal drug delivery system. Int. J Pharm Tech Res. 2010; 2(1):68-77.

[30] Divya A, Rao MK, Gnanprakash K, Sowjanya A, Vidyasagar N, Gobinath M. A review on current scenario of transdermal drug delivery system. Int. J Res. Pharm Sci. 2012;3(4):494-502.

[31] Yadav V. Transdermal drug delivery system: review. Int. J Pharm Sci. Res. 2012;3(2):376-382.

[32] Ramteke KH, Dhole SN, Patil SV. Transdermal drug delivery system: a review. J Advanced Sci. Res. 2012; 3(1):22-35.

[33] Kumar D, Sharma N, Rana AC, Agarwal G, Bhat ZA. A review: transdermal drug delivery system: A tools for novel drug delivery sestem. Int. J Drug Dev. Res. 2011; 3 (3):70-84.

[34] Joshi K, Selvaduary G. Transdermal drug delivery system and their use of polymers. MatE 175- Biomaterials. 1st 2008:1-28.

[35] Meidan V.Ultrasound-Enhanced Transdermal Drug Delivery; Transdermal Drug Delivery,Second Edition, Marcel Dekker Inc, New York, USA; 2003.

[36] Langer R. Transdermal drug delivery: past progress, current status and future prospects. Advanced Drug Delivery Reviews 2004; 56:557 - 558.

[37] G. Agarwal, S. Dhawan. Development, Fabrication and Evaluation of Transdermal Drug Delivery System: A Review, www.pharmainfo.net. 2009.

[38] Naik A, Kalia YN, Guy RH. Transdermal drug delivery: Overcoming the skin's barrier function. PSTT. 3(9); 2009: 318-26.

[39] Wiechers J., "Use of chemical penetration enhancers in transdermal drug delivery-possibilities and difficulties", Acta Pharm, 1992, 4, 123.

[40] Srilatha M, Kottai M A. Transdermal drug delivery system: A mini review. The Pharma Innovation Journal 2019; 8(1): 181-197.

[41] Divyesh P, Nirav P, Meghal P, Navpreet K, Transdermal drug delivery system: Review International Journal of Biopharmaceutical and Toxicology Research. 2011; 1(1):61-80.